Showing 1721-1730 of 3315 results for "".
- Nicox Appoints New Chair of the Board and Directorhttps://modernod.com/news/nicox-appoints-new-chair-of-the-board-and-director/2482357/Nicox announced the appointment of the experienced healthcare executive Damian Marron as Chair of the Board of Directors. Marc Le Bozec, an experienced life sciences entrepreneur, was appointed as a new Director of Nicox. Jean-François Labbe is retir
- FDA Grants DeNovo Classification to Balance Ophthalmics' FYSX Ocular Pressure Adjusting Pumphttps://modernod.com/news/fda-grants-denovo-classification-to-balance-ophthalmics-fysxtm-ocular-pressure-adjusting-pump/2482333/Balance Ophthalmics announced that the FDA has granted DeNovo Classification of the FYSX Ocular Pressure Adjusting Pump, a new category of treatment for patients with normal tension glaucoma (NTG) and open-angle glaucoma (OAG) with IOP ≤ 21 mmHg. “The FDA classif
- Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-screened-in-the-whistler-phase-3b-trial-of-ncx-470-in-glaucoma/2482018/Nicox announced that the first patient has been screened in the Whistler phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in IOP lowering. NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is the company's le
- Novavax’s COVID-19 Vaccine Over 89% Effective in UK trial, Less So in South Africa Studyhttps://modernod.com/news/novavaxs-covid-19-vaccine-over-89-effective-in-uk-trial-less-so-in-south-africa-study/2478809/Novavax shares gained as much as 26% on Thursday after the company said its protein-based COVID-19 vaccine candidate NVX-CoV2373 met the primary endpoint of a phase 3 trial in the UK, demonstrating an efficacy rate of over 89%, with high protection also seen against the fast-spreading UK variant.
- Staar Surgical Announces Leadership Changeshttps://modernod.com/news/staar-surgical-announces-leadership-changes/2482682/Staar Surgical announced that Stephen C. Farrell, current Lead Independent Director of the Staar Board of Directors, has been appointed President and CEO, effective February 26, 2025. He is replacing Tom Frinzi, current President and CEO, who will remain with the company in an advisory role
- Johnson & Johnson Vision Reveals New Data on Blue-Violet Light Filtering Technology in Acuvue Oasys Max 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-reveals-new-data-on-blue-violet-light-filtering-technology-in-acuvue-oasys-max-1-day-contact-lenses/2481196/Johnson & Johnson Vision Care will present new data on the positive effects of wearing blue-violet light filtering contact lenses at the 2022 American Academy of Optometry (AAO) annual meeting in San Diego, October 26-29. "As a result of our increasingly digital
- Topcon Receives FDA Clearance for OCT Angiography on the Maestro2 Systemhttps://modernod.com/news/topcon-receives-fda-clearance-for-octa-on-the-maestro2-system/2482439/Topcon Healthcare has received FDA 510(k) clearance for OCT angiography (OCTA) on the company’s Maestro2 robotic OCT color fundus camera system. According to Topcon, the Maestro2 offers 3×3-mm, 4.5×4.5-mm, and 6x6-mm OCTA scans, which provide the flexibility to le
- Jeff Sieve Appointed CEO of Haag-Streit USAhttps://modernod.com/news/jeff-sieve-appointed-ceo-of-haag-streit-usa/2480518/Haag-Streit has announced that Jeff Sieve is the new Chief Executive Officer for Haag-Streit USA. Mr. Sieve begins his new role immediately, succeeding Ernest Cavin, PhD, who recently left the company to pursue new opportunities. Mr. Sieve will report to Haag-Streit Group management, le
- Vision Expo East Cancelled Due to Coronavirus; Will Consolidate With Vision Expo West in Las Vegashttps://modernod.com/news/vision-expo-east-cancelled-due-to-coronavirus-will-consolidate-with-vision-expo-west-in-las-vegas/2477359/The organizers of Vision Expo announced that they are cancelling the scheduled Vision Expo East meeting scheduled to take place in New York, March 26-29, and consolidate that meeting with Vision Expo West in Las Vegas, Sept. 23-26. The decision was made due to concerns over the spread of the coro
- Lighthouse Guild to Host Lectures on Ophthalmic Drug Approvals, Technological Innovations, and Advocacy for People with Vision Impairmenthttps://modernod.com/news/lighthouse-guild-to-host-lectures-on-ophthalmic-drug-approvals-technological-innovations-and-advocacy-for-people-with-vision-impairment/2481898/Lighthouse Guild will host three lectures on the latest advances in treatment, technology, and advocacy for people who are blind or have vision loss on Thursday, October 19, 2023, 12-1:30 pm ET, at their headquarters, 250 West 64th Street in Manhattan. Lectures: